Calcitonin Salmon (3 brand names, 2 dosage forms, 2 routes)
Available dosage forms: INJECTABLE, SPRAY, METERED.
Routes of administration: INJECTION, NASAL.
Brand Names
- CALCIMAR
- CALCITONIN-SALMON
- MIACALCIN
Related Health Topics
Related Conditions
Contraindications
Hypersensitivity to calcitonin-salmon or any of the excipients. Reactions have included anaphylactic shock, anaphylaxis, bronchospasm, and swelling of the tongue or throat [see Warnings and Precautions (5.1)].
Adverse Reactions
The following serious adverse reactions are discussed in greater detail in other sections of the label: Hypersensitivity Reactions, including anaphylaxis [see Warnings and Precautions (5.1)]. Hypocalcemia [see Warnings and Precautions (5.2)]. Nasal Adverse Reactions [see Warnings and Precautions (5.3)]. Malignancy [see Warnings and Precautions (5.4)].
Drug Interactions
No formal drug interaction studies have been performed with Calcitonin Salmon Nasal Solution. Concomitant use of calcitonin-salmon and lithium may lead to a reduction in plasma lithium concentrations due to increased urinary clearance of lithium. The dose of lithium may require adjustment.
Mechanism of Action
Calcitonin-salmon is a calcitonin receptor agonist. Calcitonin-salmon acts primarily on bone, but direct renal effects and actions on the gastrointestinal tract are also recognized. Calcitonin-salmon appears to have actions essentially identical to calcitonins of mammalian origin, but its potency per mg is greater and it has a longer duration of action. The actions of calcitonin on bone and its role in normal human bone physiology are still not completely elucidated, although calcitonin receptors have been discovered in osteoclasts and osteoblasts.
Overdosage
The pharmacologic actions of Calcitonin Salmon Nasal Solution suggest that hypocalcemic tetany could occur in overdose. Therefore, provisions for parenteral administration of calcium should be available for the treatment of overdose. Single doses of Calcitonin Salmon Nasal Solution up to 1600 International Units, doses up to 800 International Units per day for 3 days and chronic administration of doses up to 600 International Units per day have been studied without serious adverse effects.